Welcome to Chatter with BNC, Business North Carolina's weekly podcast, serving up interviews with some of the Tar Heel State's most interesting people.

 

Today's episode features an interview with Kevin O’Brien. O'Brien serves as president of North America for Merz Therapeutics, where he leads commercial strategy and execution, including field sales, managed markets, medical affairs, marketing and operations, across the U.S. and Canada. Since joining Merz in 2017, he has overseen the U.S. FDA approval of Merz’s neuromodulator for the treatment of sialorrhea (excessive drooling) and as a first-line treatment for blepharospasm, two debilitating conditions associated with neurological conditions, including Parkinson’s disease, ALS and cerebral palsy.